European Medicines Agency approves France’s new covid booster vaccination

European Medicines Agency approves France's new covid booster vaccination
European Medicines Agency approves France's new covid booster vaccination. Image: Michele Ursi/

A covid vaccine made by Sanofi and GSK finally gets approval after trial failures.

The French pharma giant Sanofi along with Britain’s GSK have recently been given approval for a new covid booster vaccine by the European Medicines Agency. The booster jab known as VidPrevtyn Beta can be used by adults who have previously received mRNA jabs like those from Pfizer/BioNTech and Moderna, according to a report in France 24 on Friday, November 11.

“A booster dose of VidPrevtyn Beta is expected to be at least as effective as Comirnaty (Pfizer’s vaccine) at restoring protection against Covid-19,” the Amsterdam-based Eupean Madicines Agency said in a report.

Both the companies had long been waiting for approval and had to start from the beginning after failing clinical trials due to dosage problems, the report states. Whereas Pfizer/BioNTech and Moderna managed to get their approval over two years ago and introduced their vaccine at a record pace, never before seen in history, the report states.

“Today’s approval validates our research in developing a novel solution for the Covid-19 pandemic,” Thomas Triomphe, Sanofi executive vice president for vaccines, said in a quote published in France 24.

According to the report, the vaccine is a combination of a Sanofi-developed antigen based on the Beta variant, which stimulates the production of antibodies, with GSK’s adjuvant technology, a substance that boosts the immune response.

The report states that the final approval of the vaccine is a big achievement for the French pharma company, who had been under scrutiny at home for being unable to manufacture a Covid vaccine in the country.

Thank you for taking the time to read this article, do remember to come back and check out the EuroNews247 website for all your up-to-date European news stories.